Premature discontinuation among individuals with epilepsy participating in epilepsy self-management research interventions.


Journal

Epilepsy research
ISSN: 1872-6844
Titre abrégé: Epilepsy Res
Pays: Netherlands
ID NLM: 8703089

Informations de publication

Date de publication:
11 2022
Historique:
received: 10 08 2022
revised: 22 09 2022
accepted: 06 10 2022
pubmed: 23 10 2022
medline: 9 11 2022
entrez: 22 10 2022
Statut: ppublish

Résumé

The Managing Epilepsy Well (MEW) Network conducts epilepsy self-management (ESM) intervention development, testing, and archival clinical trials data analyses in the MEW Network Integrated Database (MEW-DB). However, not all trial participants fully benefit from ESM due to prematurely discontinuing program participation. This analysis sought to identify demographic and clinical predictors of premature discontinuation (PD) of ESM interventions available in the MEW-DB. Data from prior studies were included if: 1) they were prospective trials testing an ESM intervention, 2) included baseline assessment and at least one post-intervention assessment, and 3) included data on PD. Dependent variables were all-cause PD, categorized as a binary variable (yes/no) and time to PD for the intervals between baseline and follow-up visit 1 (V1; approximately week 12) and visit two (V2; approximately week 24). Multivariable Cox proportional hazard models were used to identify factors affecting PD time-point. Explanatory variables included age, gender, race/ethnicity, education, employment, income, marital status, psychiatric comorbidities, depressive severity, anxiety symptoms, self-efficacy, number of anti-seizure medications (ASMs), health status, seizure frequency, and study design. Six prior MEW-DB studies were included, consisting of 627 people, where 624 were assigned to ESM or to control. PD among randomized individuals was 14.3 % by V1 and 15.7 % by V2. Predictors for V1 PD were treatment (ESM) vs. control arm, more severe depressive symptoms and having schizophrenia. Predictors for V2 PD were younger age, white race, more severe depressive symptoms and having schizophrenia. While ESM approaches can improve multiple health outcomes among people with epilepsy, nearly one in six individuals prematurely discontinues their program. These findings suggest that ESM interventionists need to be particularly attentive to program retention over the first 3 months after ESM initiation. Younger people with epilepsy, those who self-identify as white, those with schizophrenia, and/or more severe depressive symptoms may need additional support for engagement.

Identifiants

pubmed: 36272309
pii: S0920-1211(22)00185-1
doi: 10.1016/j.eplepsyres.2022.107034
pii:
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

107034

Subventions

Organisme : CDC HHS
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Farren B S Briggs (FBS)

Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, United States. Electronic address: farren.briggs@case.edu.

Kaylee Sarna (K)

Department of Psychiatry, Case Western Reserve University School of Medicine, University Hospitals of Cleveland Medical Center, Cleveland, OH, United States. Electronic address: kns17@case.edu.

Joy Yala (J)

Department of Psychiatry, Case Western Reserve University School of Medicine, University Hospitals of Cleveland Medical Center, Cleveland, OH, United States. Electronic address: jyala@kent.edu.

Cam Escoffery (C)

Rollins School of Public Health, Emory University, Atlanta, GA, United States. Electronic address: cescoff@emory.edu.

Robert T Fraser (RT)

Department of Rehabilitation Medicine, University of Washington, Seattle, WA, United States. Electronic address: rfraser@uw.edu.

Mary R Janevic (MR)

Center for Managing Chronic Disease, University of Michigan, Ann Arbor, MI, United States. Electronic address: mjanevic@umich.edu.

Barbara C Jobst (BC)

Department of Neurology, Geisel School of Medicine at Dartmouth, Dartmouth College, Lebanon, NH, United States. Electronic address: barbara.c.jobst@hitchcock.org.

Erica K Johnson (EK)

Health Promotion Research Center, University of Washington, Seattle, WA, United States. Electronic address: ericajohnsonphd@uwalumni.com.

Elaine T Kiriakopoulos (ET)

Department of Neurology, Geisel School of Medicine at Dartmouth, Dartmouth College, Lebanon, NH, United States. Electronic address: Elaine.T.Kiriakopoulos@dartmouth.edu.

Julie Rentsch (J)

Department of Psychiatry, Case Western Reserve University School of Medicine, University Hospitals of Cleveland Medical Center, Cleveland, OH, United States. Electronic address: Julie.Rentsch@UHhospitals.org.

Ross Shegog (R)

UTHealth School of Public Health, Houston, TX, United States. Electronic address: Ross.Shegog@uth.tmc.edu.

Tanya M Spruill (TM)

Department of Population Health, New York University Grossman School of Medicine, New York, NY, United States. Electronic address: tanya.spruill@nyulangone.org.

Martha Sajatovic (M)

Case Western Reserve University School of Medicine, Neurological and Behavioral Outcomes Center University Hospitals Cleveland Medical Center, Cleveland, OH, United States. Electronic address: Martha.Sajatovic@UHhospitals.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH